Orforglipron safety profile & UK regulatory status
Reference
Reviewed by the BestHealingPeptides Editorial Team ·
This page summarises the published safety profile, contraindications, interactions and UK regulatory status for Orforglipron. It is a reference and not a clinical safety assessment. Orforglipron is the active substance of the prescription only medicine Foundayo; the UK Summary of Product Characteristics on the emc is the authoritative source for safety information.
Safety profile
This section summarises the UK SmPC for Foundayo on the emc (section 4.8 unless stated); the product carries a black triangle and is subject to additional monitoring. In placebo-controlled Phase 3 studies, 4158 patients were exposed to orforglipron alone or in combination with other glucose-lowering medicines. The most frequently reported adverse reactions were gastrointestinal and were mostly mild or moderate; the incidence of nausea, vomiting and diarrhoea was higher during dose escalation and decreased over time. The MHRA lists the most common side effects as nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain.
Gastrointestinal disorders. In the placebo-controlled weight-management Phase 3 studies, gastrointestinal disorders occurred in 60.1% (6 mg capsules), 67.4% (12 mg) and 68.7% (36 mg) of patients versus 36.3% with placebo, and discontinuation due to gastrointestinal adverse reactions occurred in 3.7%, 6.3% and 6.8% versus 0.6%. In the placebo-controlled type 2 diabetes studies the corresponding figures were 43.2% (3 mg), 57.6% (12 mg) and 59.1% (36 mg) versus 25.9%, with discontinuation in 2.1%, 4.1% and 6.2% versus 0.4%. The SmPC states that orforglipron has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and should be used with caution in them (section 4.4).
Pancreatitis. Acute pancreatitis has been reported in patients treated with orforglipron. Section 4.4 states that orforglipron has not been studied in patients with a history of pancreatitis and should be used with caution in them; if pancreatitis is suspected it should be discontinued, and if the diagnosis is confirmed it should not be restarted. In weight-management studies, mean percentage increases from baseline in amylase and lipase were 18.9% and 28.8% with orforglipron versus 2.9% and 3.8% with placebo; the SmPC states their clinical significance is unknown in the absence of other signs and symptoms of pancreatitis.
Other SmPC warnings (section 4.4) and adverse reactions (section 4.8). Gastrointestinal reactions may lead to dehydration and volume depletion, which could cause acute kidney injury. Hypotension may occur and was more frequent in patients on antihypertensive therapy. Acute gallbladder disease has been reported with GLP-1 receptor agonists including orforglipron; cholelithiasis was reported in 1.3% of patients on orforglipron versus 0.6% on placebo in weight-management studies. Orforglipron has not been studied in patients receiving or planning treatment for diabetic retinopathy or macular oedema, and rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Pulmonary aspiration has been reported with long-acting GLP-1 receptor agonists in patients undergoing general anaesthesia or deep sedation. There is no experience in NYHA class IV heart failure and it is not recommended in these patients. Hair loss was reported in 3.7% of patients on orforglipron versus 1.8% on placebo in weight-management studies. Post-marketing and class reports listed in section 4.8 include non-arteritic anterior ischaemic optic neuropathy with GLP-1 receptor agonist products, and anaphylaxis and angioedema.
Hypoglycaemia. Patients taking orforglipron with an insulin secretagogue (for example a sulfonylurea) or insulin may have an increased risk of hypoglycaemia, and a reduction in the dose of the sulfonylurea or insulin may be considered.
Heart rate. Mean pulse rate increased from baseline, generally peaking during dose escalation (6.7 to 8.6 beats per minute in weight-management studies and 4.7 to 7.6 in type 2 diabetes studies), and then gradually decreased; at week 72 in weight-management studies the mean change was 3.9 to 5.2 beats per minute. Tachycardia was reported in 2.7% of patients on orforglipron versus 0.8% on placebo in the weight-management studies.
Liver. The SmPC does not recommend orforglipron in severe hepatic impairment (section 4.2); in participants with severe hepatic impairment, exposure after a single 1 mg capsule dose was 4.63-fold higher than in participants with normal hepatic function (section 5.2). A pooled analysis of seven Phase 3 trials (11,220 participants, of whom 6,920 received orforglipron; Wharton et al., Diabetes Obes Metab 2026, PMID 42338042) found mean reductions in ALT and AST with orforglipron. Six participants on orforglipron and six on comparators had ALT or AST at least 3 times the upper limit of normal with bilirubin at least 2 times the upper limit; alternative causes accounted for all the orforglipron cases, and the authors concluded that orforglipron treatment was not associated with drug-induced liver injury.
Thyroid. The SmPC (section 5.3) states that orforglipron is not pharmacologically active in rats or mice and was non-carcinogenic in a 2-year rat study and a 26-week transgenic mouse study. For other GLP-1 receptor agonists that are active in rodents, thyroid C-cell hyperplasia and neoplasia have been observed and are considered a class effect; the relevance for humans is considered low but cannot be completely excluded. The UK SmPC section 4.3 lists hypersensitivity as the only contraindication. The US label (DailyMed) carries a boxed warning for the risk of thyroid C-cell tumours and contraindicates use in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Trial safety context. In ACHIEVE-3, gastrointestinal events, discontinuations due to adverse events and the mean increase in pulse rate were higher with orforglipron than with oral semaglutide (PMID 41765029). In ACHIEVE-4, gastrointestinal adverse events were reported in 62.1% of orforglipron participants versus 14.2% on insulin glargine, and clinically significant or severe hypoglycaemia in 6.8% versus 19.2% (PMID 42815506). Suspected side effects can be reported to the MHRA Yellow Card scheme.
Reported contraindications & cautions
- Hypersensitivity to the active substance or to any of the excipients (the only contraindication listed in UK SmPC section 4.3)
- Pregnancy: should not be used during pregnancy; discontinue at least 3 weeks before a planned pregnancy because of the half-life, and women of childbearing potential should use effective contraception (SmPC section 4.6; a caution rather than a section 4.3 contraindication)
- Breast-feeding: the SmPC (section 4.6) states that orforglipron should not be used during breast-feeding; it is not listed in section 4.3
- Severe hepatic impairment: not recommended (SmPC sections 4.2 and 5.2)
- History of pancreatitis: not studied, use with caution; if pancreatitis is confirmed, orforglipron should not be restarted (SmPC section 4.4)
- Severe gastrointestinal disease, including severe gastroparesis: not studied, use with caution (SmPC section 4.4)
- Dehydration from gastrointestinal effects may lead to acute kidney injury (SmPC section 4.4)
- Hypotension: may occur and was more frequent with concomitant antihypertensive therapy (SmPC section 4.4)
- Diabetic retinopathy: not studied in patients receiving or planning treatment for retinopathy or macular oedema; rapid improvement in glucose control has been associated with a temporary worsening (SmPC section 4.4)
- General anaesthesia or deep sedation: pulmonary aspiration has been reported with long-acting GLP-1 receptor agonists (SmPC section 4.4)
- NYHA class IV heart failure: no experience, not recommended (SmPC section 4.4)
- Medullary thyroid carcinoma or MEN 2: a contraindication and boxed warning in the US label, but not a contraindication in the UK SmPC (section 4.3 lists hypersensitivity only); discuss any personal or family history with the prescriber
- Concomitant use with another GLP-1 receptor agonist: the US label states this is not recommended (limitation of use); it is not a contraindication in UK SmPC section 4.3, which lists hypersensitivity only
Known interactions (product label)
- Strong CYP3A4 inhibitors: clarithromycin increased orforglipron AUC 3.5-fold and Cmax 1.9-fold; the maximum dose is the 9 mg tablet once daily with a strong CYP3A4 inhibitor (for example ketoconazole, clarithromycin, itraconazole). Strong CYP3A4 inhibitors that also inhibit OATP1B (for example ritonavir, telaprevir) should be avoided (SmPC sections 4.2 and 4.5).
- OATP1B inhibitors: cyclosporine increased orforglipron AUC 2.6-fold and Cmax 1.3-fold; the maximum dose is 9 mg once daily with a clinical OATP1B inhibitor (SmPC sections 4.2 and 4.5).
- CYP3A4 inducers: carbamazepine decreased orforglipron AUC by 82% and Cmax by 55%. Strong inducers (for example rifampicin, phenytoin, St John's wort) should be avoided, and effectiveness should be monitored with moderate inducers (SmPC section 4.5).
- Oral hormonal contraceptives: orforglipron may reduce their efficacy; switch to a non-oral method or add a barrier method for 30 days after starting orforglipron and for 30 days after each dose escalation (SmPC section 4.5).
- Simvastatin: exposure to the active metabolite simvastatin acid was increased up to 2.5-fold, and the SmPC states the simvastatin dose should be halved. Rosuvastatin: caution when the rosuvastatin dose exceeds 20 mg. Oral topotecan: monitor for adverse reactions (SmPC section 4.5).
- Delayed gastric emptying: when paracetamol and orforglipron were co-administered, paracetamol Cmax decreased by 28%; the SmPC states that no clinically relevant effect on commonly administered medicines is expected based on modelling (section 4.5).
- Sulfonylureas and insulin: increased hypoglycaemia risk; a reduction in the dose of the sulfonylurea or insulin may be considered. Metformin and SGLT2 inhibitors can be continued unchanged (SmPC sections 4.2, 4.4 and 4.5).
- Interaction studies were conducted with the hard capsule form (SmPC section 4.5).
UK regulatory status
Orforglipron is licensed in the United Kingdom as Foundayo, a prescription only medicine. The MHRA announced on 10 August 2026 that it had authorised orforglipron (Foundayo), and the UK SmPC gives 10 August 2026 as the date of first authorisation (section 9). The marketing authorisation holder is Eli Lilly Nederland B.V. The emc lists Foundayo film-coated tablets as six separate products, one per strength (0.8 mg, product 102527, PL 14895/0369; 2.5 mg, 102528, PL 14895/0370; 5.5 mg, 102529, PL 14895/0371; 9 mg, 102530, PL 14895/0372; 14.5 mg, 102531, PL 14895/0373; 17.2 mg, 102532, PL 14895/0374), with the same SmPC text apart from strength and licence number. The emc page was last updated on 14 August 2026, and the product is subject to additional monitoring (black triangle).
Section 4.1 of the SmPC lists two indications: (1) as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial BMI of 30 kg/m2 or more (obesity), or 27 kg/m2 to under 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity, for example prediabetes or type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease; and (2) treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise, as monotherapy or in combination with other medicinal products for the treatment of diabetes. The SmPC states that the safety and efficacy of orforglipron in children aged less than 18 years have not been established (section 4.2).
NHS availability. The gov.uk announcement states that the tablet is not currently available via the NHS, and that decisions on NHS use will follow established processes, including an evaluation by the National Institute for Health and Care Excellence (NICE). This page does not summarise any NICE guidance on orforglipron; check NICE for the current position.
Supply. The MHRA states that all GLP-1 medicines are prescription only medicines, which means they can only be obtained from a registered pharmacy with a prescription from a doctor, and that buying GLP-1 medicines from unregulated sellers carries serious health risks. Orforglipron sold as a research chemical is not the licensed product.
Outside the UK. The US FDA approved Foundayo on 1 April 2026 (NDA 220934) for adults with obesity, or overweight with at least one weight-related comorbid condition; the US label has no type 2 diabetes indication, and Lilly's second-quarter 2026 results list a US type 2 diabetes submission under regulatory progress. In the EU, the CHMP adopted a positive opinion on 15 October 2026 recommending a marketing authorisation for type 2 diabetes and weight management; a European Commission decision had not been confirmed when this page was last updated, so orforglipron should not be described as approved in the EU.
Orforglipron is not named on the WADA Prohibited List; athletes should check the current List with their anti-doping organisation.
Medicine status
Unlike most compounds on this site, orforglipron is a licensed prescription only medicine in the UK (Foundayo, for weight management and for type 2 diabetes) rather than an unlicensed research chemical. The gov.uk announcement states that it is not currently available via the NHS. Anyone prescribed it should follow their prescriber's advice and the patient information leaflet.
For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.
For full Orforglipron research context including mechanism, study citations, and references, see the main Orforglipron research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.